Cargando…
The Effect of the PCSK9 Inhibitor Evolocumab on Aldosterone Secretion among High Cardiovascular Risk Patients: A Pilot Study
Elevated low-density lipoprotein (LDL) cholesterol is one of the leading causes of cardiovascular disease. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce LDL cholesterol levels with subsequent reductions in cardiovascular morbidity. Elevated aldosterone levels are also assoc...
Autores principales: | Izkhakov, Elena, Shacham, Yacov, Serebro, Merav, Yaish, Iris, Marcus, Yonit, Shefer, Gabi, Tordjman, Karen, Greenman, Yona, Stern, Naftali, Ziv-Baran, Tomer |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8201266/ https://www.ncbi.nlm.nih.gov/pubmed/34198795 http://dx.doi.org/10.3390/jcm10112504 |
Ejemplares similares
-
SUN-042 Low Dose Cyproterone Acetate for the Treatment of Transgender Women - a Retrospective Study
por: Even-Zohar, Naomi, et al.
Publicado: (2020) -
Severe Hyponatremia With Partial Hypoadrenalism in Acute Porphyria
por: Marcus-Perlman, Yonit, et al.
Publicado: (2021) -
Unknown Subclinical Hypothyroidism and In-Hospital Outcomes and Short- and Long-Term All-Cause Mortality among ST Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention
por: Izkhakov, Elena, et al.
Publicado: (2020) -
OR25-5 High Prevalence of Psychopathologies Among Transgender Subjects Presenting at a Large Tertiary Transgender Health Center: Implication for the Treating Clinicians
por: Kerem, Gil, et al.
Publicado: (2019) -
Endocrinology specialty service for inpatients: an unmet growing need
por: Osher, Esther, et al.
Publicado: (2023)